DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
MMSI logo

Merit Medical Systems, Inc. Stock Price

NasdaqGS:MMSI Community·US$5.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

MMSI Share Price Performance

US$87.19
-1.60 (-1.80%)
​
US$100.27
Fair Value
US$87.19
-1.60 (-1.80%)
13.0% undervalued intrinsic discount
US$100.27
Fair Value
Price US$87.19
AnalystConsensusTarget US$100.27
AnalystLowTarget US$83.00
AnalystHighTarget US$121.70
Fri, 14 Aug 26
Fair ValueUS$100.27
Share Pricen/a

MMSI Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$100.27 13.0% undervalued intrinsic discount

Global Aging And Healthcare Demand Will Expand Medical Procedures

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$83 5.0% overvalued intrinsic discount

Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$121.7 28.4% undervalued intrinsic discount

Oncology And Endoscopy Platforms Will Reshape Long Term Earnings Power

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
MMSI logo
Merit Medical Systems
13.0% undervalued intrinsic discount

Global Aging And Healthcare Demand Will Expand Medical Procedures

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 14 Aug
Read Narrative
MMSI logo
Merit Medical Systems
28.4% undervalued intrinsic discount

Oncology And Endoscopy Platforms Will Reshape Long Term Earnings Power

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 3 Sep
Read Narrative
MMSI logo
Merit Medical Systems
5.0% overvalued intrinsic discount

Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 31 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
MMSI logo

MMSI: Raised Guidance And Margin Outlook Will Drive Future Repricing Potential

Fair Value: US$121.7 28.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
MMSI logo

MMSI: Raised 2026 Outlook And Rich P/E Suggest Fairly Balanced Setup

Fair Value: US$100.27 13.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
MMSI logo

MMSI: Strong Q2 Execution And 2026 Guidance Will Test Earnings Power

Fair Value: US$83 5.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet with proven track record.

1 Risk
3 Rewards
View Full Analysis

Merit Medical Systems, Inc. Key Details

US$1.6b

Revenue

US$797.1m

Cost of Revenue

US$781.7m

Gross Profit

US$636.2m

Other Expenses

US$145.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
2.44
49.51%
9.22%
43.8%
View Full Analysis

About MMSI

Founded
1987
Employees
7500
CEO
Martha Aronson
WebsiteView website
www.merit.com

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

Recent MMSI News & Updates

User avatar
Narrative Update • Sep 03

MMSI: Raised Guidance And Margin Outlook Will Drive Future Repricing Potential

Analysts have lifted the fair value estimate for Merit Medical Systems to about $121.70 from $110, reflecting updated assumptions for slightly stronger revenue growth, higher profit margins, and a modestly higher future P/E in line with recent price target increases across the Street. Analyst Commentary Recent research updates on Merit Medical Systems show a clear cluster of more optimistic views on the stock, with several firms lifting price targets following the latest Q2 report and updated guidance.

Recent updates

No updates

Merit Medical Systems, Inc. Competitors

IDXX logo

IDEXX Laboratories

Symbol: NasdaqGS:IDXX
Market cap: US$40.6b
CNC logo

Centene

Symbol: NYSE:CNC
Market cap: US$31.9b
DXCM logo

DexCom

Symbol: NasdaqGS:DXCM
Market cap: US$31.9b
RMD logo

ResMed

Symbol: NYSE:RMD
Market cap: US$31.6b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide